Return to Provider News

Pfizer voluntarily recalls Chantix

Audience: Providers of impacted members

The U.S. Food and Drug Administration (FDA) announced on September 16, 2021 that the drug manufacturer Pfizer is voluntarily recalling all lots of Chantix 0.5 mg and 1 mg tablets due to the presence of a nitrosamine, N-nitroso-varenicline, a probable human carcinogen (a substance that could cause cancer). As alternative suppliers have been approved in the United States, Pfizer is undertaking this precautionary measure.

Providers with questions regarding this recall can contact Pfizer using the below information.

Contact Center

Contact Information

Area of Support

Pfizer Medical Information

800-438-1985, option 3 (Mon.-Fri. 9 am-5 pm ET)
www.pfizermedinfo.comExternal Link Disclaimer

For medical questions regarding the product

Pfizer Drug Safety

800-438-1985, option 1 (24 hours a day; 7 days a week)

To report adverse events and product complaints

A list of your patients who may have filled a prescription for Chantix over the last four months is provided below. We have notified these patients of the Chantix removal from the market and advised them to contact you to discuss alternative medications to treat their health condition. 

Related News
Jubilant Cadista Recalls Losartan

Update to Preferred Therapy for Pulmonary Arterial Hypertension Drugs Effective September 1, 2021

Velcade® is the Preferred Therapy over Kyprolis® for certain indications

Change in Coverage for Basaglar® for Medicaid Managed Care Members




IE Browser Modal